DNA methylation and gene silencing in cancer

Nature Clinical Practice Oncology

Volumn 2, Issue SUPPL. 1, 2005, Pages

  Baylin, Stephen B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chromatin; DNA methylation; Gene silencing; Histone modifications

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ALIPHATIC CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; AZACITIDINE; BENZAMIDE DERIVATIVE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; GENOMIC DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CHROMATIN STRUCTURE; CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; EPIGENETICS; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY LOSS; HUMAN; MAINTENANCE THERAPY; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASMS;

EID: 31344466008     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0354     Document Type: Review

References (50)

1. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21
2. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
3. Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054
4. Merlo A et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692
5. Leone G et al. (2002) DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 87: 1324-1341
6. Daskalakis M et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964
7. Ruter B et al. (2004) DNA methylation as a therapeutic target in hematologic disorders: Recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 80:128-135
8. Galm O et al. (online) The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev, February 2005
9. Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395-2402
10. Herman JG et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875
11. Esteller M et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354
12. Okano M et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257
13. Okano M et al. (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19: 219-220
14. Rhee I et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556
15. Rhee I et al. (2000) CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404: 1003-1007
16. Fuks F et al. (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24: 88-91
17. Robertson KD et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25: 338-342
18. Rountree MR et al. (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277
19. Fuks F et al. (2001) Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 20: 2536-2544
20. Bachman KE et al. (2001) Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem 276: 32282-32287
21. Jenuwein T and Allis CD (2001) Translating the histone code. Science 293: 1074-1080
22. Bannister AJ et al. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120-124
23. Nakayama J et al. (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110-113
24. Noma K et al. (2001) Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 293: 1150-1155
25. Bird AP and Wolffe AP (1999) Methylation-induced repression-belts, braces, and chromatin. Cell 99: 451-454
26. Marks PA et al. (2000) Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216
27. Mei S et al. (2004) Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol 25: 1509-1519
28. Drummond DC et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528
29. Cameron EE et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107
30. Suzuki H et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149
31. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162
32. Esteller M et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10: 3001-3007
33. Grady WM et al. (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26: 16-17
34. Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9: 359-367
35. Herman JG et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704
36. Bender CM et al. (1998) DNA methylation as a target of drug design. Pharmaceut Res 15: 175-187
37. Santini V et al. (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586
38. Herman JG et al. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841
39. Christiansen DH et al. (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17: 1813-1819
40. Wales MM et al. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570-577
41. Chen W et al. (2004) Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6: 387-398
42. Chen WY et al. (2003) Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33: 197-202
43. Glover AB and Leyland-Jones B (1987) Biochemistry of azacitidine: A review. Cancer Treat Rep 71: 959-964
44. Robertson KD and Jones PA (2000) DNA methylation: Past, present and future directions. Carcinogenesis 21: 461-467
45. Juttermann R et al. (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797-11801
46. Silverman LR (2001) Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6: 8-14
47. Creusot F et al. (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacitidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041-2048
48. Goffin J and Eisenhauer E (2002) DNA methyltransferase inhibitors - state of the art. Ann Oncol 13: 1699-1716
49. Aparicio A and Weber JS (2002) Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3: 627-633
50. Luebbert M (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 249: 135-164